|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current assets: | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Investments | |||||||||||||||
| Prepaid and other current assets | |||||||||||||||
| Total current assets | |||||||||||||||
| Investments, noncurrent | |||||||||||||||
| Property and equipment, net | |||||||||||||||
| Other assets | |||||||||||||||
| Total assets | |||||||||||||||
| Liabilities and stockholders’ equity | |||||||||||||||
| Current liabilities: | |||||||||||||||
| Accounts payable | |||||||||||||||
| Accrued liabilities | |||||||||||||||
| Senior secured term loan, current portion | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Long-term liabilities: | |||||||||||||||
| Senior secured term loan, net of current portion | |||||||||||||||
| Total liabilities | |||||||||||||||
| Convertible preferred stock | |||||||||||||||
| Stockholders’ equity: | |||||||||||||||
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 88,530,322 and 81,536,557 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Total stockholders’ equity | |||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...